Additionally, IL-1β is ubiquitous in the molecular pathogenesis of a chronic inflammatory diseases such as arthritis, cardiovascular disease, and autoimmune conditions (46), and clinical trials have demonstrated the potency of blocking IL-1β to ameliorate the molecular and systemic manifestations of these diseases (47–49). Here, IL1B is linked to arthritic joint disease.